Sysmex Europe
Menu

News

Company news articles found here detail internal and external events that may be interesting for all stakeholders. Whether it’s CSR activities, product launches, collaborations or reports on events, you can stay up-to-date on the latest Sysmex news.

Our latest Sysmex news
Here you can find the latest official press releases and current company news from Sysmex EMEA.
  • All Years
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
2022/11/03 | PRODUCT

OGT launches SureSeq™ Myeloid Plus panel and Universal NGS Complete Workflow

Launch of several new solutions to support OGT’s growing NGS portfolio
2022/10/03 | CORPORATE

Sysmex and JCR Pharmaceuticals Establish a Joint Venture in the Field of Regenerative Medicine and Cell Therapy

Aiming for the Research & Development and Early Commercialization of Regenerative Medicine Products Using Stem Cells, etc.
2022/09/27 | PRODUCT

Sysmex Launches the UF-1500 Fully Automated Urine Particle Analyzer, a New Product for the Urine Sediment Testing Field

Product Lineup Expanding for Small and Medium-sized Facilities
2022/08/24 | CORPORATE

OGT significantly expands global reach

Expansion of access to clinical support network and market-leading genomic solutions aims to improve patient outcomes
2022/08/01 | CORPORATE

Pilot, Inc. Becomes Wholly-owned Sysmex Subsidiary Through the Acquisition of Outstanding Shares

Reinforcing Software Design and Development Capabilities
2022/07/01 | PRODUCT

Sysmex Launches Sample Transportation System Modules for XR™-Series of Automated Hematology Analyzer

The world’s first automated quality control material measurements contribute to greater automation and efficiency in clinical testing
2022/07/01 | PRODUCT

Sysmex Europe has launched the XQ-520 fully automated haematology analyser

Out now: Sysmex XQ-520 3PD haematology analyser
2022/06/27 | PRODUCT

Completion of Declaration of Conformity to the European IVD Directive for an Assay Kit that Measures Plasma Amyloid Beta (Aβ) Using the Automated Immunoassay System HISCL™-5000/HISCL™-800

Testing Method that Assists in the Identification of Aβ Accumulation in the Brain
2022/06/10 | CORPORATE

Bayerische Hausbau and MATRIX lay the foundation stone for the new work campus FLOW in Hamburg

The new work campus FLOW in Hamburg is becoming a reality: The MATRIX Group and Bayerische Hausbau laid the foundation stone today together with anchor tenant Sysmex Europe and the Second Mayor Katharina Fegebank.
2022/05/27 | CORPORATE

The Ajinomoto Foundation, Sysmex, and NEC initiate a cross-industry co-creation project to improve maternal and child health and nutrition in the Republic of Ghana

Contributing to Universal “Nutrition” Health Coverage
2022/05/25 | PRODUCT

Sysmex Europe SE and Sysmex Inostics GmbH launch two CE-IVD certified Plasma-SeqSensei™ liquid biopsy kits: Solid Cancer IVD Kit and Breast Cancer IVD Kit

Sysmex Inostics, a global leader in blood-based circulating tumour DNA (ctDNA) analysis, together with Sysmex Europe SE, announce the introduction of two IVD-certified Plasma-SeqSensei™ (PSS) kits to the EMEA region.
2022/05/02 | CORPORATE

Astrego Diagnostics AB Becomes Wholly-owned Sysmex Subsidiary through the Acquisition of Outstanding Shares

Commercialization of Rapid Antimicrobial Susceptibility Test to Reinforce Structure for Promoting AMR Countermeasures
2022/04/28 | CORPORATE

Sysmex Employee to Receive “Medal with Purple Ribbon” in Spring 2022 Medal of Honor Awards

Sysmex Corporation employee Toshihiro Mizukami has been selected to receive the Medal with Purple Ribbon, one of the medals of honor to be bestowed in spring 2022.
2022/04/22 | CORPORATE

Sysmex Europe ranks among Germany’s Top 100 employers by Great Place To Work®

Sysmex Europe is proud to announce that Sysmex Europe SE is listed in the top 100 best workplaces by Great Place To Work® Deutschland again this year. It is ranked 17th in the ‘501-2000 employees’ category.
2022/04/11 | PRODUCT

Sysmex Europe has launched its new three-part differential automated haematology analyser XQ-320, adding excellence in quality to this important market segment

Sysmex Europe has recently launched its new three-part differential system ‘XQ-320 XQ-Series Automated Haematology Analyser’, answering to the needs of this important high-volume market segment.
2022/04/11 | PRODUCT

Sysmex Europe launches CE-IVD-marked Flow Cytometer XF-1600, offering clinical flow cytometry laboratories robust and reliable immunophenotyping

Sysmex Europe, a trusted provider of automated workflow solutions in the disciplines of haematology, urinalysis and haemostasis, announces the launch of its Flow Cytometer XF-1600 which has received CE marking, indicating its compliance with the European IVD Regulation and IVD use.
2022/03/01 | CORPORATE

Sysmex Europe will exhibit at the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine in Munich, Germany, 11–13 April 2022

Sysmex Europe will be present at the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, which will take place in Munich, Germany, from 10 to 14 April 2022.
2022/02/15 | CORPORATE

Sysmex Establishes Subsidiary in Saudi Arabia

Reinforcing Sales, Service, and Support Structures to Expand Business in a Growing Market
2022/01/18 | CORPORATE

Sysmex R&D Center Europe and “academist” begin collaborating in providing academic research funds in Europe

“academist” and Sysmex R&D Center Europe collaborate in exploring and granting academic research in Europe in the healthcare area at the European universities’ research labs. Scientific researchers can apply for the research funds through academist’s website.
2022/01/05 | PRODUCT

Sysmex Files for Manufacturing and Marketing Approval for an Assay Kit that Assists in Identification of Amyloid Beta (Aβ) Accumulation in the Brain

Measurement of Plasma Aβ Using Automated Immunoassay System HISCL-5000/HISCL-800
2021/12/08 | CORPORATE

Discover the fighter in you – through our latest antimicrobial resistance (AMR) awareness campaign!

The 2021 #AMRfighter campaign to raise awareness of antimicrobial resistance shows us that making small changes can make a big difference to help mitigate the growing problem.
2021/10/20 | PRODUCT

Sysmex Europe and Inpeco launch the next gamechanger in urinalysis

Read more about the first and only bi-directional system that transports racks between the Sysmex UN-Series urinalysis analysers and Inpeco's TLA system.
2021/10/15 | CORPORATE

Sysmex Europe wins awards in the programme ‘Excellence in learning 2021’ by Brandon Hall Group

Following the success in 2019, Sysmex Europe receives two bronze awards for ‘Best customer training program’ and ‘Best advance in creating a learning strategy’ by the Brandon Hall Group this year.
2021/10/04 | PRODUCT

Sysmex Launches Caresphere™ XQC, an External Quality Assessment App

Enhancing the Reliability of Testing Results and Efficiency of Laboratory Operations with the Expansion of Caresphere
2021/09/30 | CORPORATE

Sysmex Europe plans new working environments in the new headquarters in Hamburg

The Sysmex Group, international manufacturer and provider of innovative analytical instruments and services for laboratory diagnostics, is on a continuous course of growth and innovation. To accommodate this development, Sysmex Europe will relocate its headquarters for the EMEA region (Europe, Middle East and Africa) from Norderstedt to Hamburg.
2021/09/14 | PRODUCT

Sysmex launches its Sample Preparation System PS-10 in EMEA – a new product to make clinical flow cytometry testing more efficient

Sysmex Europe GmbH announces the launch of the automated flow cytometry sample preparation system PS-10 in the EMEA region.
2021/07/13 | PRODUCT

Sysmex launches new products for the haemostasis field in the EMEA region: automated blood coagulation analysers CN-3500 and CN-6500 using chemiluminescence enzyme immunoassay (CLEIA) technology to enhance the testing workflow

Sysmex Europe GmbH launches new haemostasis analysers CN-3500 and CN-6500 that can run chemiluminescence enzyme immunoassays to enhance the testing workflow.
2021/07/12 | PRODUCT

Sysmex and Inpeco announce the connection of the CN-3000/CN-6000 haemostasis analysers to the FlexLab™ Laboratory Automation System

Sysmex is expanding its haemostasis solution portfolio and is collaborating with Inpeco once again. Three Sysmex haemostasis analysers – starting with CS-5100, and now CN-3000 and CN-6000 – are connectable to Inpeco’s FlexLabTM Total Laboratory Automation System.
2021/06/18 | PRODUCT

Sysmex launches HISCL™-5000 and the HISCL™ SARS-CoV-2 Ag Assay Kit in EMEA.

Sysmex Europe GmbH announces the launch of the HISCL™-5000 fully automated random-access immunochemistry analyser and the HISCL™ SARS-CoV-2 Ag Assay Kit in the EMEA region.
2021/06/16 | PRODUCT

Sysmex obtains the first IVDR certification for LYNOAMP™ CK19 E, a Gene Amplification Detection Reagent

Sysmex Europe GmbH announced today that LYNOAMP CK19 E, part of OSNATM method using a molecular biological technique for cancer diagnostics, is the first Sysmex product to be certified by a notified body under the new European In Vitro Diagnostic Medical Devices Regulation (IVDR) on 4 June 2021
2021/06/07 | CORPORATE

Patient stratification and prognostic scores – the value of routine diagnostic parameters in supporting COVID-19 disease management

Identification of COVID-19-positive patients upon hospital admission usually relies on RT-PCR tests, however, clinicians can utilise diagnostic information to make decisions during the first examination of a patient as well. If risk factors are already known, this can be combined with laboratory tests to provide an informed initial evaluation.
2021/04/06 | PRODUCT

Sysmex and Inpeco announce the launch of a new solution that will change the way of urinalysis

Sysmex and Inpeco will collaborate to bring a game-changer to the field of urinalysis. They will combine their experience and expertise to launch an interface solution to the market in Fall 2021.
2021/04/01 | PRODUCT

Sysmex launches Plasma-SeqSensei™ liquid biopsy RUO kits in EMEA

Sysmex Europe GmbH, together with Sysmex Inostics GmbH, announced today that they will launch the Plasma-SeqSensei™ liquid biopsy research use only (RUO) kits for colorectal cancer (CRC), non-small cell lung cancer (NSCLC), melanoma and thyroid cancer.
2021/03/31 | CORPORATE

Sysmex Europe and Sysmex Germany rank among Germany’s Top 100 employers by Great Place to Work®

Sysmex Europe GmbH, together with Sysmex Deutschland GmbH, is officially ranked among Germany’s top 100 employers by Great Place to Work®.
2021/03/08 | CORPORATE

Sysmex Presents Academic Report on Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood

Presenting the Most Recent Data at the 15th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2021)
2021/02/03 | CORPORATE

Sysmex Corporation Announces Business Results for the First Nine Months of the Fiscal Year Ending March 31, 2021

Sysmex’s announced today the business result of the first nine months of the fiscal year ending March 31, 2021.
2021/02/03 | CORPORATE

Sysmex and Siemens Healthineers Extend Long-standing Global Alliance in Hemostasis Testing

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and Siemens Healthcare Diagnostics Inc. (HQ: NY, U.S.A.; hereinafter, "Siemens Healthineers") today announced that, on February 2, 2021, the two companies agreed to extend their long-standing alliance on global supply, distribution, and sales and service for hemostasis products through at least 2023. 
2021/02/03 | CORPORATE

Sysmex establishes new subsidiary in Portugal

Increasing Portuguese Market Presence by Enhancing Sales and After-Sales Support Networks
2021/01/26 | CORPORATE

Sysmex Selected as One of the Global 100's Most Sustainable Companies in the World for the Fourth Time

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announced today that, it has been selected as one of the 2021 Global 100's Most Sustainable Companies in the World, a ranking conducted by Canadian publisher Corporate Knights.
2021/01/25 | CORPORATE

Sysmex and Roche Renew Agreement for Global Alliance

Transforming a long-standing alliance into one for the next generation
2021/01/14 | CORPORATE

Sysmex Europe GmbH again awarded with certificate for audit berufundfamilie

Sysmex has again received the berufundfamilie certification, recognising family-friendly working conditions and more.
2020/12/23 | PRODUCT

Sysmex Obtains Marketing Approval for the HISCL™ IFN-λ3 Assay Kit, a Test Kit to Assist in Determining Exacerbation Risk in Novel Coronavirus (SARS-CoV-2)-Positive Patients

Target market: Japan
2020/12/18 | CORPORATE

Sysmex Europe GmbH among top 3 employers for IT jobs in MedTech sector

Sysmex Europe GmbH has been named the top 3 German companies for top employers in IT in the MedTech sector. The top picks are surveyed and presented by CHIP and GreatJobs.
2020/12/11 | CORPORATE

Sysmex EMEA’s first virtual congress, Sysmex Expo 2020 – a great success!

From 8-10 December, Sysmex EMEA hosted their first ever virtual congress.
2020/12/04 | CORPORATE

Sysmex America, Inc. attends the global AACC Annual Scientific Meeting & Clinical Lab Expo

Our colleagues on the other side of the globe, Sysmex America, Inc., will be participating in this year’s AACC Annual Scientific Meeting & Clinical Lab Expo. Typically held in a different American city each year, this year’s event will be held virtually.
2020/12/03 | PRODUCT

Sysmex Launches Surgical Robot Unit, hinotoriTM Surgical Robot System

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announced today that it will launch the hinotori Surgical Robot System, a surgical robot unit, and the HF Series Instrument, a reusable active endotherapy device (collectively referred to as "hinotori" hereinafter; manufacturer: Medicaroid Corporation [HQ: Kobe, Japan; President: Kaoru Asano]) on December 4, 2020 for medical institutions in Japan.
2020/11/11 | PRODUCT

Sysmex Obtains Manufacturing and Marketing Approval for a SARS-CoV-2 Antigen Detection Reagent

Detecting SARS-CoV-2 Antigens Using Fully Automated Immunoassay Systems HISCL™-5000 / HISCL™-800
2020/11/09 | CORPORATE

Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood - CTAD

The Content Presented at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
2020/11/05 | CORPORATE

"Conquering the wave" – preparing for the second wave of COVID-19

Sysmex Global Webinar for COVID-19
2020/10/29 | PRODUCT

Sysmex Presents Academic report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood

Presenting the Most Recent Data at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
2020/10/28 | CORPORATE

Sysmex Europe is one of Germany's best companies for apprentices

For the fourth time, the business magazine CAPITAL, together with the talent platform Ausbildung.de and the personnel marketing experts from TERRITORY EMBRACE, has set out to find Germany's best company for apprentices. 
2020/10/26 | PRODUCT

Sysmex Europe GmbH and affiliates now distributors for Genedrive® 96 SARS-CoV-2 Kit

Genedrive® 96 SARS-CoV-2 Kit is a real-time RT-PCR test for the qualitative detection of SARS-CoV-2 nucleic acids. It addresses the need for high-volume throughput testing and is now being distributed by Sysmex Europe.
2020/10/09 | CORPORATE

Sysmex Europe is celebrating 40 years of diagnostic advancement and growth

Sysmex Europe GmbH celebrates 40 years of business in EMEA and looks forward to continuing lighting the way with diagnostics.
2020/09/29 | PRODUCT

Sysmex Applies for Manufacturing and Marketing Approval for a SARS-CoV-2 Antigen Detection Reagent

Detecting SARS-CoV-2 Antigens Using Fully Automated Immunoassay Systems HISCL™-5000 / HISCL™-800
2020/08/19 | CORPORATE

Updates & information on COVID-19

According to the increasing incidence of COVID-19 worldwide and in particular in EMEA (Europe, Middle East and Africa), we have reviewed our activities and escalated our preventive measures.
2020/08/11 | PRODUCT

Medicaroid receives Japanese regulatory approval for the “hinotori™ Surgical Robot System”, the first made-in-Japan robotic assisted surgery system

Medicaroid Corporation (HQ: Kobe, Japan; President: Kaoru Asano; hereinafter referred to as Medicaroid) announces it received regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the hinotori™ Surgical Robot System.
2020/08/11 | PRODUCT

Collaboration of Medicaroid, Kawasaki Heavy Industries and Sysmex for the business of the“hinotori™ Surgical Robot System”, a robotic assisted surgery system

Medicaroid Corporation (HQ: Kobe; President: Kaoru Asano; hereinafter referred to as Medicaroid) announces the Japanese regulatory approval for the hinotori™ Surgical Robot System.
2020/07/27 | PRODUCT

Sysmex Launches OncoGuide™ NET Expert Panel Support System in Cancer Genome Profiling

- Supporting the Establishment of a System for Efficient Cancer Genomic Medicine -
2020/07/27 | PRODUCT

Sysmex Launches Lab Assay Service for Research on Cytokines Related to the Novel Coronavirus (SARS-CoV-2)

- Aiming to Monitor the Risk of Increasing Severity and Treatment Effects in Clinical Applications-
2020/07/14 | PRODUCT

Sysmex launches next-generation fully automated blood coagulation analysers CN-6000 and CN-3000 in EMEA

Power in a new dimension for the haemostasis laboratory
2020/07/03 | PRODUCT

Sysmex to Launch Novel Coronavirus (SARS-CoV-2) Antibody Lab Assay Service and Antibody Measurement Reagents (for Research)

Using the HISCL™-5000/HISCL™-800 Fully Automated Immunoassay Systems to Realize SARS-CoV-2 Antibody Detection
2020/07/03 | CORPORATE

The City of Kobe, Kobe City Medical Center General Hospital, and Sysmex Corporation Working to Launch from Kobe the Clinical Implementation of a New Test for the Novel Coronavirus

Collaborating with Medical Institutions of the Foundation for Biomedical Research and Innovation at Kobe to Strengthen Measures Allowing Early-Stage Diagnosis and Prediction of Severity
2020/07/03 | CORPORATE

The National Cancer Center, the National Center for Global Health and Medicine, and Sysmex Corporation Evaluatea SARS-CoV-2 Antibody Test with Support from the Japan Health Research Promotion Bureau

Performance Report onan Antibody Detection Reagent Using Clinical Specimens
2020/07/02 | PRODUCT

Sysmex Obtains First Marketing Approval in Japan for the Automated Hematology Analyzer XN-31 as a Class III Specially Controlled Medical Device to Diagnose Malaria

For Use as a Measure against Imported Infectious Diseases in Japan and Accelerating its Introduction to the Asian and African Markets
2020/06/01 | CORPORATE

Sysmex and OPTiM Jointly Establish New Company to Plan, Develop and Operate Medical AI and IoT Open Platforms and Digital Transformation Solutions

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and OPTiM Corporation (HQ: Minato-ku, Tokyo, Japan; President: Shunji Sugaya) jointly established and began conducting operations at D’PULA Medical Solutions Corporation on June 1, 2020. The company is in charge of planning, developing, and operating solution services that leverage open platforms and applications related to digital medicine.
2020/05/29 | PRODUCT

OSNA label extension for cervical, endometrial and prostate cancer

OSNA (One Step Nucleic Acid Amplification), a molecular diagnostic assay for accurate detection and quantification of lymph node metastases, is now available also for cervical, endometrial and prostate cancer. 
2020/05/25 | CORPORATE

Sysmex Donates ¥30 Million to Kobe City Support Fund for Medical Professionals to Support COVID-19 Countermeasures

Our thoughts and prayers are with the families of those who have perished as a result of the novel coronavirus (COVID-19), and we offer our heartfelt sympathy to the patients currently suffering from this disease. We are truly grateful for the efforts of the medical community and all others who are working on the front lines to stop this pandemic from spreading. Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has decided to donate ¥30 million to the Kobe City Support Fund for Medical Professionals to support measures for countering COVID-19.
2020/03/27 | PRODUCT

Sysmex Obtains First Marketing Approval in Japan for the Novel Coronavirus Nucleic Acid Detection Kits (RT-PCR Method)

Aiming for early introduction of test kits forin vitrodiagnostic medical devicesin medical institutions
-Japanese market only-
2020/03/05 | CORPORATE

Sysmex Presents Academic Report Related to the Clinical Utility of RAS Gene Mutation Testing for Colorectal Cancer Using Liquid Biopsy

Details of Report on Clinical Utility of OncoBEAM™ RAS CRC Kit presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2020 (ASCO-GI 2020)
2020/02/10 | PRODUCT

Magseed® magnetic marker approved for any soft tissue and long-term implantation across Europe

Endomag has received an extended indication for the long-term use of the Magseed® magnetic marker in any soft tissue. The extended indication was approved after the Magseed® marker was found to be accurate and easy to place in the breast and the armpit in a number of clinical studies. CE certification widening follows the 510(k) clearance from the U.S. Food and Drug Administration (FDA), which was received for the same indication already in 2018.
2020/01/29 | CORPORATE

Sysmex Invests in Astrego Diagnostics with a View to Developing New Urinalysis Solutions for the Primary Care Business

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has reached an agreement to invest in Astrego Diagnostics AB (HQ: Uppsala, Sweden; CEO: Ove Öhman). Through this investment, Sysmex aims to help commercialize a rapid drug susceptibility test that Astrego is developing for urinary tract infections.
2020/01/14 | PRODUCT

Hitado GmbH becomes Nexus IB10 distributor for sphingotec in Germany and Switzerland

Hitado GmbH (Hitado), a Sysmex point-of-care subsidiary, and SphingoTec GmbH (sphingotec) have signed an exclusive distribution agreement for the commercialisation of the Nexus IB10 diagnostic platform by Hitado in Germany. Further, Sysmex Suisse AG will commercialise the platform in Switzerland.
2020/01/14 | CORPORATE

Sysmex gives back – supporting social development together

Science and diagnostics are fascinating – at least that’s what we at Sysmex believe. When the opportunity comes along to fuel excitement for science together with other knowledge providers, we take it.
2019/12/20 | PRODUCT

OSNA for lung cancer – the newest addition to our oncology portfolio

OSNA, a molecular assay for accurate detection of lymph node metastases, is now available for lung cancer!
2019/12/02 | CORPORATE

Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood

Presenting the Most Recent Data at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
2019/11/29 | CORPORATE

Sysmex Europe GmbH wins Silver Technology Award from the 2019 Learning In Practice Awards Program by Chief Learning Officer magazine.

Learning awards seem a little bit like in the movie industry – you may get one in one category, but there are always more categories where you can win!
2019/11/07 | CORPORATE

Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31

Sysmex’s announced today the financial results of the first six months of the fiscal year ending March 31.
2019/11/05 | CORPORATE

Sysmex Wins Awards in 2019 Kinki Local Commendations for Innovations

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) received a Minister of Education, Culture, Sports, Science and Technology Prize, and Encouragement Prizes for Inventions, at the Kinki* Local Commendation for Inventions, sponsored by the Japan Institute of Invention and Innovation.
2019/11/01 | CORPORATE

Sysmex and OPTiM Reach a Basic Agreement on the Establishment of a Joint Venture to Accelerate the Commercialization of Digital Medicine to Support Next-Generation Healthcare and Diagnostics

Aiming toward the Early-Stage Provision of Platforms and Applications Related to Digital Medicine
2019/10/30 | CORPORATE

Industry, Government and Academia Jointly Establish a General Incorporated Association to Promote the Bioresource Business

Jointly Established by Kobe University, the City of Kobe, the Foundation for Biomedical Research and Innovation at Kobe, and Sysmex
2019/10/02 | CORPORATE

Knowledge Is Power - Celebrating 10 Years of Sysmex Academy and More

Medical diagnostics company Sysmex Europe GmbH celebrates the 10th anniversary of the Sysmex Academy in October. Sysmex is the only company to have such a longstanding education system in place for both employees, distributors, and later on, end-customers.
2019/09/19 | PRODUCT

Sysmex Launches Caresphere™ QM, an Operational Support System for Testing Quality Management

Realizing the Operation of High-Quality Clinical Laboratories through our New Caresphere™ Solution
2019/09/17 | CORPORATE

Sysmex Selected for Inclusion in the Dow Jones Sustainability World Index for the Fourth Consecutive Year

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces that it has been selected for inclusion in the Dow Jones Sustainability World Index (DJSI World), a leading global index of ESG investment, for the fourth consecutive year.
2019/09/06 | CORPORATE

Sysmex Europe GmbH wins the Silver Award for ‘Best Customer Training Program’ from the 2019 Brandon Hall Group Excellence in Learning Awards

The nomination was based on the customer learning portal – Sysmex Academy – that would supplement the face-to-face training with a broad selection of digital training media and live webinars.
2019/09/03 | CORPORATE

Japan’s First Automated Hematology Analyzer Registered by the National Museum of Nature and Science as “Essential Historical Material for Science and Technology”

-Using Unique Technology to Cultivate True Automation in Blood Cell Counting-
2019/08/29 | CORPORATE

Hamburg leaders visited Sysmex Corporation in Kobe

At the end of August, a delegation of high-ranking representatives, including Hamburg’s First Mayor Dr Peter Tschentscher, spent one day in Kobe as part of their tour of Japan and China.
2019/07/19 | PRODUCT

Liquid Biopsy performance comparison of Sysmex Inostics OncoBEAM RAS CRC and BioCartis Idylla ctKRAS testing published in Scientific Reports (Nature Journal)

Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces publication of a study comparing the performance of plasma RAS mutation detection by two commercial liquid biopsy testing platforms, the OncoBEAM™ RAS CRC and the Idylla ctKRAS Mutation Test from the BioCartis Group NV.
2019/06/13 | PRODUCT

A welcome addition to our portfolio: Sentinel’s SENTiFOB® analyser with new cap-piercing function, ideal for low-middle throughput, for the detection of faecal occult blood using FOBGold® reagents

To extend its faecal immunochemical testing (FIT) line to cover the low sample throughput segment of faecal occult blood testing (FOBT), Sentinel Diagnostics recently relaunched its SENTiFOB® analyser with a new cap-piercing function. This add-on feature translates into a new and competitive hardware solution in this market segment.
2019/06/04 | PRODUCT

World Anti-Doping Agency Coordinates Global Implementation of Sysmex Analyzers at All Blood Laboratories

Contributing to Clean and Fair Sports Management by Enhancing the Quality of Doping Tests
2019/05/30 | PRODUCT

Sysmex Inostics OncoBEAM™-EGFR digital PCR liquid biopsy demonstrates two-fold higher detection of p.T790M mutations in 183 NSCLC patients in comparison study

Sysmex Inostics announces the publication of clinical research conducted as part of the CIRculating CANcer (CIRCAN) Program at the Lyon Cancer Institute (Lyon, France) comparing the performance of Sysmex Inostics BEAMing (beads, emulsion, amplification, and magnetics) assay for EGFR resistance mutations (OncoBEAM-EGFR) to a next-generation sequencing assay (56G Oncology Panel from Swift Biosciences) in non-small cell lung cancer (NSCLC) patients with EGFR sensitizing mutations under first-line tyrosine kinase inhibitor (TKI) therapy.
2019/05/28 | PRODUCT

Sysmex Inostics’ SafeSEQ ER+/HER2- breast cancer panel demonstrates equivalent sensitivity to OncoBEAM™ enhanced digital PCR technology for detection of mutations in circulating tumor DNA

Recent data presented by Dr. Hope S. Rugo from the University of California San Francisco on behalf of investigators in the Translational Breast Cancer Research Consortium at the American Association of Cancer Research 2019 meeting in Atlanta, Georgia demonstrate how Sysmex Inostics’ novel SafeSEQ ER+/HER2- breast cancer panel can detect clinically relevant mutations in circulating tumor DNA (ctDNA) from patients with metastatic breast cancer with sensitivity equivalent to Sysmex’s highly clinically validated OncoBEAM liquid biopsy testing.
2019/05/13 | CORPORATE

Sysmex Europe GmbH was awarded as ‘Top Employer SME 2019’ and ranked 8th in the category ‘Electronics and Electrical Engineering, Medical Devices’

The award is based on the results of independent data collection carried out by the business magazine FOCUS-Business in cooperation with the employer assessment platform kununu.
2019/05/08 | CORPORATE

Promoting Business Process Restructuring through Digitalization to Reinforce Corporate Foundations and Create New Value

To achieve business process restructuring, we will construct a digital foundation for the corporate management functions that underpin the Group management foundation, as well as for the value chain encompassing research and development, procurement and logistics, manufacturing, and sales and service.
2019/05/08 | CORPORATE

Sysmex Opens Technopark East Site, a Bio-Diagnostic Reagent Base

Strengthening Diagnostic Reagent Functions through an Integrated Structure from the Development of Substances to the Development, Production and Distribution of Bio-Diagnostic Reagents
2019/04/25 | PRODUCT

Sysmex Obtains CE Certification for Automated Hematology Analyzer XN-31, Which Has an Automatic Measurement Function for Red Blood Cells Infected by Malaria Parasites

Contributing to the Early Detection and Treatment of Malaria through Standardized and More Efficient Malaria Testing
2019/03/01 | CORPORATE

Sysmex to Be Special Sponsor of the Kobe Marathon 2019

-We are pleased to have sponsored this exciting event since its inception in 2011-
2018/12/04 | CORPORATE

Sysmex Europe GmbH organises a blood donation and sport event on 3 December

On 3 December, Sysmex Europe GmbH and Sysmex Deutschland GmbH hosted a blood donation and charity event to give back to society. “Be a Hero” was the motto of the event, which showed a large turnout.
2018/12/04 | PRODUCT

With a View to New Value Creation, Sysmex Launches a Research Assay Service for HDL Function Measurement

-Aiming to Prevent Atherosclerosis-Related Diseases and Provide Treatment Opportunities-
2018/12/03 | PRODUCT

Sysmex Launches Revohem FIX Chromogenic, a Blood Coagulation Factor IX Measurement Kit

-Japan’s First Coagulation Factor IX Measurement Kit Using Chromogenic Assay, Helping to Diagnose and Assist in the Treatment of Hemophilia B-
2018/11/28 | CORPORATE

Sysmex and MolecularMD Commence Global Partnership to Address the Challenges in Companion Diagnostics Development and Commercialization

-To Accelerate Precision Medicine Through Globally Proven Experience-
2018/11/26 | PRODUCT

CALiaGold – The new quantitative immunoassay from Sentinel Diagnostics for calprotectin measurement in SENTiFIT 270 Analyser

Sysmex Europe GmbH and Sentinel Diagnostics will continue their partnership, which now also gives Sysmex Europe the distribution rights for Sentinel's newest FIT line assay: CALiaGold. CALiaGold is a quantitative latex immunoassay for Calprotectin measurement in faeces. 
2018/11/05 | PRODUCT

Sysmex Inostics OncoBEAM™ circulating tumor DNA technology demonstrates superior response prediction for advanced pancreatic cancer over standard-of-care protein biomarkers

Recent data published in Annals of Oncology from a study conducted by Sysmex Inostics and University of Munich indicate that circulating tumor DNA (ctDNA) may offer clinicians higher-resolution information for response prediction and therapy monitoring for advanced pancreatic cancer patients compared to current established protein biomarkers. 
2018/10/26 | CORPORATE

Congratulations to our CEO Hisashi Ietsugu!

Popular management magazine Harvard Business Review (HBR) recently published their 2018 ranking of the world’s top-performing CEOs. Jumping nine places from 2017’s rankings, Hisashi Ietsugu was placed as number nine this year.
2018/10/22 | CORPORATE

Strengthening Our Global R&D Structure to Foster Early-Stage Innovation

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has decided to reinforce its global R&D structure to accelerate R&D that leverages local characteristics.
2018/10/18 | PRODUCT

Sysmex Inostics´ OncoBEAM™ platform demonstrates superior detection of clinically-relevant mutations for therapy selection and molecular monitoring for lung and colon cancers

Data presented at the European Society of Medical Oncology (ESMO) 2018 meeting in Munich, Germany by three clinical oncology research groups demonstrate the importance of a highly sensitive test for detection of clinically-relevant mutations present in circulating tumor DNA (ctDNA) derived from a simple blood draw.
2018/10/02 | CORPORATE

In vitro diagnostics company Sysmex Europe announces executive leadership change

Sysmex Europe GmbH, which oversees Sysmex’s operations in EMEA (Europe, Middle East & Africa), has announced its Chairman and long-time President & CEO Dr Jürgen Schulze decided in early 2018 to retire effective 30 September 2018, however will continue to benefit and support Sysmex as a member and vice-chairman of the MedTech Europe Executive Board.
2018/09/28 | PRODUCT

Sysmex Inostics announces launch of OncoBEAM™ EGFR Kit v2 (RUO) in Europe and Asia

Sysmex Inostics, a subsidiary of Sysmex Corporation and a global leader in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, announces the launch of the OncoBEAM™ EGFR Kit v2 for research use only in Europe and Asia. OncoBEAM™ EGFR Kit v2 replaces the EGFR v1 kit and joins Sysmex Inostics’ OncoBEAM™ RAS CRC and BRAF assays which enable laboratories to perform highly sensitive ctDNA analysis of colon and non-small cell lung cancer samples.
2018/08/31 | PRODUCT

Sysmex, Toppan Printing, and RIKEN GENESIS Commence Launch of Fully Automated System (Research Use Only) to Detect Gene Mutations in Cancer Tissue

-Streamlining the Gene Testing Processes to Standardize the Testing-
2018/08/08 | PRODUCT

Sysmex Partec’s CyFlow™ Counter System, a System to Test for CD4+ Lymphocytes, Receives WHO Prequalification

-Aiming to Help Improve the Quality of HIV Diagnosis and Treatment in Emerging Markets and Developing Countries-
2018/08/07 | CORPORATE

Sysmex and JVCKENWOOD Jointly Establish Company to Use Micro and Nano-Fabrication Technology to Develop and Manufacture IVD Biodevices

These in vitro diagnostic (“IVD”) devices will consist of microfluidics to achieve rapid reactions among tiny amounts of specimens and reagents. Creative Nanosystems is expected to commence R&D in October 2018, toward the commercialization of biodevices.
2018/07/10 | CORPORATE

Sysmex Establishes Subsidiary in Egypt and Begins Conducting Direct Sales and Services

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has established a new subsidiary in Egypt and will begin conducting direct sales and services with the aim of expanding its business in the Middle East.
2018/06/27 | CORPORATE

Sysmex, the Foundation for Biomedical Research and Innovation at Kobe, and Kyoto University Begin Joint Research on Technologies for Diagnosing Immunological Diseases

Through joint research, the three organizations aim to create a diagnostic system that will enable the early detection of autoimmune disease and chronic inflammatory disease.
2018/05/14 | PRODUCT

Sysmex Launches New Products in Its System for the Testing of Cancer Lymph Node Metastasis Using the OSNA™ Method: Gene Amplification Detector RD-200 and LYNOAMP™ CK19

-Contributing to Standardization in the Testing of Cancer Lymph Node Metastasis by Shortening Testing Times and Augmenting Processing Capacity-
2018/05/09 | CORPORATE

Sysmex Group Formulates New Long-Term Management Goals

Celebrating Our 50th Anniversary by Taking on New Challenges to Move to the Next Stage
2018/05/09 | CORPORATE

Sysmex Announces “Sysmex Eco-Vision 2025”

—To contribute to a sustainable society—
2018/05/08 | CORPORATE

Sysmex to Establish Bio-Diagnostic Reagent Center

Reinforcing Our Diagnostic Reagent Development and Production Function by Establishing a Location to Handle Integrated Development through Production and Distribution of Bio-Diagnostic Reagents
2018/05/02 | CORPORATE

Sysmex Employee to Receive the “Medal with Purple Ribbon,” a Spring 2018 Medal of Honor

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) employee Junya Inoue has been selected to receive the Medal with Purple Ribbon, medals of honor to be bestowed in spring 2018, for the development of an automated urinalysis analyzer using flow cytometry technology.
2018/04/26 | CORPORATE

Sysmex to Launch JICA Project in the Republic of Ghana: "Collaboration Program for Disseminating Automated Urinalysis Diagnosis Technology”

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) responded to a call by the Japan International Cooperation Agency (JICA) for proposals under the second fiscal 2017 Collaboration Program with the Private Sector for Disseminating Japanese Technology for Social and Economic Development of Developing Countries.
2018/04/09 | CORPORATE

Sysmex Europe GmbH to Transfer Management of All European Installations of The DigniCap Scalp Cooling System Back to Dignitana AB

Dignitana AB, world leader in clinically superior scalp cooling technology, will assume the complete operation from Sysmex Europe GmbH of their DigniLife scalp cooling division.
2018/04/06 | PRODUCT

Sysmex Launches Caresphere™, a New Network Solution

Supporting the Intelligent Use of Information for the Healthcare of the Future, Where the Use of Information is Accelerating
2018/04/03 | PRODUCT

Advanced Medical Care Approval Received for Multiplex Gene Panel Testing to Advancing Personalized Medicine

On April 1, 2018, Multiplex Gene Panel Testing to Advancing Personalized Medicine using the system developed jointly by the National Cancer Center (Location: Tokyo, Japan; President: Hitoshi Nakagama) and Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) received approval as Advanced Medical Care. We will begin providing this testing from April 9, 2018.
2018/04/03 | CORPORATE

Sysmex Formulates New Corporate Message:“Lighting the way with diagnostics”

Today, we will begin rolling out this new message globally, throughout the Sysmex Group.
2018/03/21 | CORPORATE

Japan’s first-ever industry-academia alliance to realize the development of innovative medicine in Japan

Implementation of a one-stop bioresource project in Kyoto University, and the establishment of KBBM Co., Ltd. as a model of “industry-in-the-academia” industry-academia partnership
2018/03/18 | PRODUCT

OncoBEAM™ RAS CRC liquid biopsy test now reimbursed in Germany by BARMER

Effective immediately, cancer patients insured by BARMER now have access to Sysmex’s OncoBEAM™ RAS CRC IVD test.
2018/03/09 | CORPORATE

Sysmex to Be Special Sponsor of the Kobe Marathon 2018

-We are pleased to have sponsored this exciting event since its inception in 2011-
2018/02/20 | CORPORATE

Sysmex Celebrates Its 50th Anniversary of Establishment

Gratitude for All the Support over the Past 50 Years and a Commitment to Continue Taking on Challenges toward the Advancement of Healthcare.
2018/02/08 | CORPORATE

Sysmex Middle East in Medlab exhibition 5-8 February 2018 in Dubai- UAE

Sysmex is creating new opportunities, involving more and more stakeholders, and increasingly getting to the root of the core issues our healthcare clients face.
2018/01/22 | PRODUCT

In depth: Performance comparison of OncoBEAM RAS CRC and Idylla ctKRAS liquid biopsy testing for KRAS mutation detection presented at ASCO GI 2018

Sysmex Inostics, a global leader in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today highlights results presented at the American Society of Clinical Oncology’s Gastrointestinal Cancer Symposium (ASCO GI) comparing plasma KRAS mutation detection performance between two commercial liquid biopsy testing platforms, OncoBEAM RAS CRC and Idylla ctKRAS Mutation Test. 
2018/01/17 | CORPORATE

Liquid Biopsy performance comparison of OncoBEAM RAS CRC and Idylla ctKRAS testing presented at ASCO GI 2018 meeting

Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces data from an abstract of a study comparing the performance of plasma RAS mutation detection performance by two commercial liquid biopsy testing platforms, OncoBEAM RAS CRC and Idylla ctKRAS Mutation Test.
Copyright © Sysmex Europe SE. All rights reserved.
Customize your experience

We use cookies to enable you to optimally use our Website and to improve our communication with you. We shall take your selection into account and use only the data for which you give us your consent.

* May lead to restrictions in content and in the user experience
Detail about cookies
Essential cookies
These cookies help to make our website usable by enabling basic features such as page navigation and access to secure areas of our website. Our website cannot function properly without these cookies.
Statistics cookies
By collecting information anonymously, these cookies help us to understand how visitors interact with our website. This information enables us to continually improve our platform.
Marketing cookies
are used to track visitors on websites. The intention is to show advertisements that are relevant and appealing to the individual user and are, therefore, valuable to publishers and third-party advertisers.